Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41081 | ISIN: CA23809L2075 | Ticker-Symbol: D4G0
Tradegate
06.06.25 | 13:33
0,081 Euro
+6,62 % +0,005
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
DATAMETREX AI LIMITED Chart 1 Jahr
5-Tage-Chart
DATAMETREX AI LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0680,08306.06.
0,0700,08106.06.
ACCESS Newswire
353 Leser
Artikel bewerten:
(2)

DataMetrex AI Ltd.: Datametrex Acquires Arbutus Health And Wellness Inc.

TORONTO, ON / ACCESS Newswire / June 6, 2025 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that further to its news release dated April 1, 2025, it has completed the acquisition of all of the issued and outstanding share capital of Arbutus Health and Wellness Inc. ("Arbutus Health"), a multidisciplinary medical clinic in Vancouver, Canada.

Arbutus Health provides walk-in services, family medicine, skin laser treatments, and other specialty healthcare services in a single location. Once operational, the clinic will be staffed by licensed healthcare professionals and will provide patients with access to multiple medical services without requiring multiple referrals.

The acquisition of Arbutus was completed by way of a share exchange agreement dated June 5, 2025 between the Company, Arbutus and the shareholders of Arbutus pursuant to which Datametrex acquires 100% of the issued and outstanding shares of Arbutus Health, an arm's length party, in exchange for an aggregate of 11,000,000 common shares of Datametrex at a deemed value of $0.10 per share (the "Payment Shares"). As a result of the transaction, Arbutus is now a wholly-owned subsidiary of Datametrex.

Upon completion of the Transaction, Paul Haber, the CEO of the Company, commented, "We are excited to finalize this agreement and are eager to integrate the Arbutus Health team into Datametrex. This acquisition marks a key milestone in broadening our product portfolio and enhancing our presence in the healthcare sector."

Issuance of the Payment Shares is subject to the receipt of regulatory approvals including, without limitation, the final approval of the TSX Venture Exchange ("TSXV") and other conditions.

Datametrex has not assumed any debt of Arbutus and the proposed acquisition will not constitute a fundamental change or result in a change of business for the Company, nor is it expected to result in a change of control of the Company within the meaning of applicable securities laws and defined in the polices of the TSXV.

About Arbutus Health

Arbutus Health is a multidisciplinary medical clinic designed to address wait times and fragmented care in Canada's health system. Walk-in services, family doctors, skin laser treatments, and other specialties are integrated under one roof to provide timely and comprehensive care without requiring multiple referrals. Staffed by licensed healthcare professionals, patient satisfaction will be enhanced through innovative, efficient, and high-quality healthcare solutions.

About Datametrex

Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.

For more on Datametrex, please visit our Company website.

For Additional Information

Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
info@datametrex.com
(416) 318-6501

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.

While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.

Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.

This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.

SOURCE: Datametrex AI Ltd.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/datametrex-acquires-arbutus-health-and-wellness-inc.-1036191

© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.